Kardigan Reports Q3 2026 Net Loss of $58.6 Million, Advances Clinical Programs
Kardigan reported a third-quarter 2026 net loss of $58.6 million, compared with $60.2 million a year earlier, and ended September with $591.4 million in cash, cash equivalents and investments. The company completed enrollment in two Phase 2b trials and expects topline results from its danicamtiv an…